Cardio-HART for Commissioners:
Invest in Early Detection,
Save Lives and Costs

Spend Millions. Save Billions.

By deploying Cardio-HART for commissioners across NHS ICS/ICBs or regional healthcare systems, a one-time investment prevents billions in downstream costs:

Immediate & Long-Term Impact

Why Cardio-HART for commissioners Delivers ROI

1. Cut Low-Value Testing

2. Prevent Crisis Care

3. Promote Health Equity

Environmental & Social Co‑Benefits

  • Healthcare travel equals ~17% of NHS carbon emissions6.
  • Each transthoracic echo emits ~1 kg CO₂e—inclusive of travel, power, and equipment7.
  • Scaling Cardio‑HART could reduce community echo volume by 100,000s/year—cutting CO₂ and supporting NHS Net Zero.
Grandmother embraced by granddaughter, symbolizing patient-centred cardiac care with Cardio-HART for commissioners
Grandmother and granddaughter smiling together, showing patient-centred care with Cardio-HART for commissioners

Patient-Centred Care—No Trade-Offs

Cardio‑HART is patient-focused and system-smart:

  • Convenient: Simple GP-based test with no hospital visit
  • Rapid: All results in under 10 minutes—allowing same-day decisions
  • Accurate: 96% agreement with echocardiography for key conditions
  • Lower burden: Fewer hospital visits ease stress on families

Public Health, Regional, and National Goals Alignment

  • Supports NHS Long Term Plan: earlier HF diagnosis, reduced low‑value diagnostics.
  • Meets Diagnostics Recovery & Renewal objectives for better capacity use.
  • National climate targets: aligns with NHS net zero by reducing travel and imaging footprint.

Summary Table

Business meeting between healthcare decision-makers discussing Cardio-HART’s cost-effectiveness and implementation strategy.

The Bottom Line

A modest investment in Cardio‑HART transforms cardiac care at low cost:

  • Better, earlier diagnosis
  • Lower system-wide costs
  • Healthier, happier patients
  • Progress toward carbon neutrality

If you’d like to understand potential ROI for your ICS region or Spain’s regional health authority, just ask—we’ll run the numbers.

Download your PowerPoint for commissioners in England or Spanish healthcare decision-makers!

Let’s Discuss How Cardio-HART Fits Into Your Regional Strategy

Contact us to explore clinical data, cost-effectiveness, and implementation options tailored to your area.

References & Data Sources

  1. NICE pilot: Echo referrals fell from 39% to 32% post NT‑proBNP use³. ↩︎
  2. HF Report: ~£4,000 per acute HF hospital admission⁴. ↩︎
  3. Only 18.9% of patients had NT‑proBNP tested—leading to many echo referrals⁴. ↩︎
  4. 75% of HF patients diagnosed in hospital; nearly 50% via A&E⁴. ↩︎
  5. Echo use varies 4-fold between urban vs rural regions in Australia⁵. ↩︎
  6. Patient travel accounts for ~17% of NHS carbon emissions⁶. ↩︎
  7. CO₂e per echo = 0.5–2 kg; echo is lowest among imaging but not zero⁷. ↩︎